Safety of a Topical Antifungal Treatment for Tinea Cruris, Tinea Pedis and Tinea Corporis
NCT ID: NCT01349998
Last Updated: 2013-01-23
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
604 participants
INTERVENTIONAL
2011-05-31
2012-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Topical Antifungal Treatment for Tinea Pedis
NCT01396785
Topical Antifungal Treatment for Tinea Pedis
NCT01396811
Topical Antifungal Treatment for Tinea Cruris
NCT01342315
Multicenter Study of the Efficacy and Safety of Luliconazole Cream in Tinea Pedis (Athlete's Foot)
NCT00869336
A Study to Evaluate TMI-358 in the Treatment of Distal Subungual Onychomycosis
NCT01093118
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Safety Population
Product 33525
Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Product 33525
Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
12 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tinea Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Fremont, California, United States
Los Angeles, California, United States
Miami, Florida, United States
Miramar, Florida, United States
St. Petersburg, Florida, United States
Augusta, Georgia, United States
Evansville, Indiana, United States
Warren, Michigan, United States
Omaha, Nebraska, United States
Paramus, New Jersey, United States
Albuquerque, New Mexico, United States
Cincinnati, Ohio, United States
Hershey, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Goodletsville, Tennessee, United States
Austin, Texas, United States
College Station, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Lynchburg, Virginia, United States
Belize City, Belize District, Belize
San Salvador, , El Salvador
San Pedro, Sula, Honduras
Cidra, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MP-1005
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.